#Switzerland #Lausanne #Xsensio #Biosensing #Lab-on-Skin

Xsensio SA Successfully Secures $7 Million in Series A Fundraising

Xsensio SA, a pioneering deep-tech company based in Switzerland, has recently announced the successful closure of a $7 million oversubscribed Series A funding round. This strategic investment aims to accelerate the clinical deployment of its innovative continuous biosensing technology. The funding round was led by San Francisco's WI Harper, along with significant participation from Privilège Ventures, the European Innovation Council, and a diverse group of private investors from the United States, Europe, and Asia.

This new capital injection is expected to bolster Xsensio's development and clinical validation of its portable biosensing platform, known as Lab-on-Skin©. Designed to enable real-time monitoring of multiple biochemical markers, this technology promises to provide clinicians with dynamic and multimodal biochemical insights, enhancing decision-making in hospital settings and beyond.

Esmeralda Megally, the CEO of Xsensio, heralded this funding milestone as a critical advancement in the implementation of continuous biochemical monitoring in real clinical environments. She expressed, "For the first time, clinicians can access real-time, continuous key biochemical data—information that was previously unavailable at the point of care. This capability has the potential to fundamentally improve how patients are monitored and treated."

In tandem with this announcement, Xsensio disclosed a long-term collaboration with Texas Instruments, a global leader in semiconductor technology. This partnership leverages Texas Instruments' unique expertise in CMOS integration, miniaturization, and large-scale manufacturing of biosensing systems, thereby enhancing the industrial scalability of Xsensio's technology.

Adrian Ionescu, Xsensio's Chief Technology Officer, underscored the significance of the collaboration with Texas Instruments, stating, "Our partnership greatly accelerates our journey towards advanced scalable semiconductor technology. By combining our innovations in biosensing with world-class expertise in semiconductor technology, we are building a platform designed not just for clinical impact but also for reliable and cost-effective deployment."

Wilson Wu, a partner at WI Harper, remarked on Xsensio's potential, stating, "We believe Xsensio is setting a new standard in portable biosensing. Given the strong growth trajectory of the company and its commercial potential, we are excited to lead this investment round. Continuous biochemical monitoring represents a significant shift towards real-time data, and Xsensio is exceptionally positioned to drive this transformation."

Furthermore, Jaqueline Ruedin Rüsch, the Chairwoman of the Board, highlighted the game-changing nature of continuous biochemical monitoring, noting the transition from intermittent measurements to real-time insights.

About Xsensio

Xsensio stands at the forefront of innovative biosensing technology, utilizing its Lab-on-Skin© platform to deliver continuous, real-time biochemical insights tailored for personalized and preventive healthcare. The company is born out of cutting-edge university research and collaborates extensively with leading hospitals and industrial partners, striving to bring clinically significant biosensing innovations to patients in hospitals and beyond. In 2025, Xsensio was recognized by TIME as one of the world’s best health technology companies.

For media inquiries, please contact:
Esmeralda Megally, CEO and Co-founder, Xsensio SA
Email: [email protected]
Website: www.xsensio.com